| Infigratinib is a Reversible Inhibitor and Mechanism-based Inactivator of Cytochrome P450 3A4 LWT Tang, JW Teng, RK Verma, SK Koh, L Zhou, ML Go, H Fan, ... Drug Metabolism and Disposition 49 (9), 856-868, 2021 | 17 | 2021 |
| Mechanism-based inactivation of cytochrome P450 3A4 by benzbromarone LWT Tang, RK Verma, H Fan, ECY Chan Molecular Pharmacology 99 (4), 266-276, 2021 | 14 | 2021 |
| Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminates in Mechanism-Based Inactivation of Cytochrome P450 3A LWT Tang, W Wei, RK Verma, SK Koh, L Zhou, H Fan, ECY Chan Drug Metabolism and Disposition 50 (5), 529-540, 2022 | 12 | 2022 |
| Metabolic activation of the acrylamide michael acceptor warhead in futibatinib to an epoxide intermediate engenders covalent inactivation of CYP3A LWT Tang, J Fu, SK Koh, G Wu, L Zhou, ECY Chan Drug Metabolism and Disposition 50 (7), 931-941, 2022 | 11 | 2022 |
| Mechanism-Based Inactivation of Cytochrome P450 3A4 and 3A5 by the Fibroblast Growth Factor Receptor Inhibitor Erdafitinib LWT Tang, JW Teng, SK Koh, L Zhou, ML Go, ECY Chan Chemical Research in Toxicology 34 (7), 1800-1813, 2021 | 11 | 2021 |
| Identification of infigratinib as a potent reversible inhibitor and mechanism-based inactivator of CYP2J2: nascent evidence for a potential in vivo metabolic drug-drug … LWT Tang, G Wu, ECY Chan Journal of Pharmacology and Experimental Therapeutics 382 (2), 123-134, 2022 | 9 | 2022 |
| Differential Reversible and Irreversible Interactions between Benzbromarone and Human Cytochrome P450s 3A4 and 3A5 LWT Tang, RK Verma, RP Yong, X Li, L Wang, Q Lin, H Fan, ECY Chan Molecular Pharmacology 100 (3), 224-236, 2021 | 8 | 2021 |
| Atypical kinetics of cytochrome P450 enzymes in pharmacology and toxicology JWH Leow, LWT Tang, ECY Chan Advances in Pharmacology 95, 131-176, 2022 | 7 | 2022 |
| Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents HL Tan, LWT Tang, SY Chin, ECY Chan Drug Metabolism and Pharmacokinetics 38, 100390, 2021 | 7 | 2021 |
| Tissue-Specific microRNA expression profiling to derive novel biomarkers for the diagnosis and subtyping of small B-Cell lymphomas SSS Hue, Y Jin, H Cheng, MS Bin Masroni, LWT Tang, YH Ho, DBL Ong, ... Cancers 15 (2), 453, 2023 | 4 | 2023 |
| Metabolic activation of drugs by cytochrome P450 enzymes: Biochemical insights into mechanism-based inactivation by fibroblast growth factor receptor inhibitors and chemical … LWT Tang, ECY Chan Biochemical Pharmacology 206, 115336, 2022 | 4 | 2022 |
| Quantification of the irreversible fibroblast growth factor receptor inhibitor futibatinib by UPLC-MS/MS: Application to the metabolic stability assay in human liver microsomes … LWT Tang, ECY Chan Journal of Pharmaceutical and Biomedical Analysis 214, 114731, 2022 | 4 | 2022 |
| Rational deuteration of dronedarone attenuates its toxicity in human hepatic HepG2 cells LWT Tang, RYR Lim, G Venkatesan, ECY Chan Toxicology Research 11 (2), 311-324, 2022 | 4 | 2022 |
| Combination Bacillus Calmette-Guérin and indoleamine 2, 3-dioxygenase 1 inhibitor therapy of murine orthotopic bladder cancer SH Lee, R Mahendran, SM Tham, TP Thamboo, DYQ Kioh, LWT Tang, ... BJU International 126 (5), 554-556, 2020 | 2 | 2020 |
| Febuxostat and its Major Acyl Glucuronide Metabolite are Potent Inhibitors of Organic Anion Transporter 3: Implications for Drug‐Drug Interactions with Rivaroxaban LWT Tang, TWH Cheong, ECY Chan Biopharmaceutics & Drug Disposition, 2022 | 1 | 2022 |
| Characterization and Applications of Permeabilized Hepatocytes in Drug Discovery S Zhang, CC Orozco, LWT Tang, J Racich, AA Carlo, G Chang, D Tess, ... The AAPS Journal 26 (3), 1-11, 2024 | | 2024 |
| Novel Multiplexed High Throughput Screening of Selective Inhibitors for Drug-Metabolizing Enzymes Using Human Hepatocytes J Liu, D Vernikovskaya, G Bora, A Carlo, W Burchett, S Jordan, LWT Tang, ... The AAPS Journal 26 (3), 1-13, 2024 | | 2024 |
| Probe Substrate Dependencies in CYP3A4 Allosteric Inhibition: A Novel Molecular Mechanism Involving F–F′ Loop Perturbations W Wei, LWT Tang, RK Verma, H Fan, ECY Chan Journal of Chemical Information and Modeling 64 (6), 2058-2067, 2024 | | 2024 |
| Characterization of CYP3A5 Selective Inhibitors for Reaction Phenotyping of Drug Candidates J Chen, LWT Tang, S Jordan, M Harrison, GM Gualtieri, E DaSilva, ... The AAPS Journal 26 (2), 26, 2024 | | 2024 |
| Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes LWT Tang, E DaSilva, K Lapham, RS Obach Drug Metabolism and Disposition, 2024 | | 2024 |
